drugset / Trial / NCT04960124

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

NCT04960124

Phase 1 Completed 24 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-42847922 in adult participants with hepatic impairment when compared to healthy participants with normal hepatic function.

Timeline

Start
2021-08-05
Primary completion
2021-11-19
Completion
2021-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule Oral

Indications

No indication recorded.